Reversol en es it fr

Reversol Brand names, Reversol Analogs

Reversol Brand Names Mixture

  • No information avaliable

Reversol Chemical_Formula


Reversol RX_link

Reversol fda sheet

Reversol FDA

Reversol msds (material safety sheet)

Reversol Synthesis Reference

No information avaliable

Reversol Molecular Weight

352.465 g/mol

Reversol Melting Point

No information avaliable

Reversol H2O Solubility

No information avaliable

Reversol State


Reversol LogP


Reversol Dosage Forms

Powder for solution

Reversol Indication

For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Reversol Pharmacology

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Reversol Absorption

No information avaliable

Reversol side effects and Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.

Reversol Patient Information

Reversol Organisms Affected

Humans and other mammals